China Reform Health Management and Services Group Co., Ltd. (SHE:000503)
China · Delayed Price · Currency is CNY 7.74
+0.11 (1.44%)
Apr 16, 2026, 3:04 PM CST
SHE:000503 Revenue
China Reform Health Management and Services Group had revenue of 74.87M CNY in the quarter ending September 30, 2025, with 19.26% growth. This brings the company's revenue in the last twelve months to 327.12M, down -11.44% year-over-year. In the year 2024, China Reform Health Management and Services Group had annual revenue of 356.90M with 8.11% growth.
Revenue (ttm)
327.12M
Revenue Growth
-11.44%
P/S Ratio
23.17
Revenue / Employee
255.76K
Employees
1,279
Market Cap
7.58B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 356.90M | 26.77M | 8.11% |
| Dec 31, 2023 | 330.13M | 19.05M | 6.12% |
| Jan 1, 2023 | 311.08M | 58.56M | 23.19% |
| Jan 1, 2022 | 252.52M | 45.14M | 21.77% |
| Dec 31, 2020 | 207.37M | 77.46M | 59.62% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| WuXi AppTec | 43.42B |
| Shenzhen Mindray Bio-Medical Electronics | 33.28B |
| Jiangsu Hengrui Pharmaceuticals Co.,Ltd | 31.63B |
| Northeast Pharmaceutical Group | 7.07B |
| Blue Sail Medical | 5.78B |
| Sichuan Biokin Pharmaceutical | 2.52B |
| Hunan Warrant Pharmaceutical Co.,Ltd | 1.52B |
| Zhejiang Garden Biopharmaceutical | 1.24B |